Daniel Sheward

Selected publications

Letter: LANCET INFECTIOUS DISEASES. 2024;24(2):e80-e81
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
Review: NATURE MICROBIOLOGY. 2023;8(11):1952-1959
SARS-CoV-2 evolution in the Omicron era
Roemer C; Sheward DJ; Hisner R; Gueli F; Sakaguchi H; Frohberg N; Schoenmakers J; Sato K; O'Toole A; Rambaut A; Pybus OG; Ruis C; Murrell B; Peacock TP
Letter: LANCET INFECTIOUS DISEASES. 2023;23(11):e462-e463
Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses
Sheward DJ; Yang Y; Westerberg M; Oling S; Muschiol S; Sato K; Peacock TP; Hedestam GBK; Albert J; Murrell B
Letter: LANCET INFECTIOUS DISEASES. 2022;22(11):1538-1540
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
Sheward DJ; Kim C; Fischbach J; Sato K; Muschiol S; Ehling RA; Bjorkstrom NK; Hedestam GBK; Reddy ST; Albert J; Peacock TP; Murrell B
Letter: LANCET INFECTIOUS DISEASES. 2022;22(10):1421-1422
Evasion of neutralising antibodies by omicron sublineage BA.2.75
Sheward DJ; Kim C; Fischbach J; Muschiol S; Ehling RA; Bjorkstrom NK; Hedestam GBK; Reddy ST; Albert J; Peacock TP; Murrell B
Article: JOURNAL OF VIROLOGY. 2022;96(14):e0032422-e00322
HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies
Sheward DJ; Hermanus T; Murrell B; Garrett N; Karim SSA; Morris L; Moore PL; Williamson C
Article: LANCET INFECTIOUS DISEASES. 2022;22(6):813-820
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
Sheward DJ; Kim C; Ehling RA; Pankow A; Dopico XC; Dyrdak R; Martin DP; Reddy ST; Dillner J; Hedestam GBK; Albert J; Murrell B
Article: CELL REPORTS MEDICINE. 2021;2(11):100450
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models
Sheward DJ; Mandolesi M; Urgard E; Kim C; Hanke L; Vidakovics LP; Pankow A; Smith NL; Dopico XC; McInerney GM; Coquet JM; Hedestam GBK; Murrell B
Article: CELL HOST & MICROBE. 2018;24(4):593-599.e3
HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth
Sheward DJ; Marais J; Bekker V; Murrell B; Eren K; Bhiman JN; Nonyane M; Garrett N; Woodman ZL; Karim QA; Karim SSA; Morris L; Moore PL; Williamson C

Articles

Article: CELL REPORTS MEDICINE. 2024;5(6):101577
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Sheward DJ; Pushparaj P; Das H; Greaney AJ; Kim C; Kim S; Hanke L; Hyllner E; Dyrdak R; Lee J; Dopico XC; Dosenovic P; Peacock TP; McInerney GM; Albert J; Corcoran M; Bloom JD; Murrell B; Hedestam GBK; Hallberg BM
Article: NPJ VACCINES. 2024;9(1):17
Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
Lenart K; Cerveira RA; Hellgren F; Ols S; Sheward DJ; Kim C; Cagigi A; Gagne M; Davis B; Germosen D; Roy V; Alter G; Letscher H; Van Wassenhove J; Gros W; Gallouet A-S; Le Grand R; Kleanthous H; Guebre-Xabier M; Murrell B; Patel N; Glenn G; Smith G; Lore K
Article: CELL REPORTS MEDICINE. 2023;4(11):101267
SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes
Wall SC; Suryadevara N; Kim C; Shiakolas AR; Holt CM; Irbe EB; Wasdin PT; Suresh YP; Binshtein E; Chen EC; Zost SJ; Canfield E; Crowe JEJ; Thompson-Arildsen MA; Sheward DJ; Carnahan RH; Georgiev IS
Article: JCI INSIGHT. 2023;8(17):e167656
Antigen receptor stimulation induces purifying selection against pathogenic mitochondrial tRNA mutations
Zhang J; Koolmeister C; Han J; Filograna R; Hanke L; Adori M; Sheward DJ; Teifel S; Gopalakrishna S; Shao Q; Liu Y; Zhu K; Harris RA; Mcinerney G; Murrell B; Aoun M; Baeckdahl L; Holmdahl R; Pekalski M; Wedell A; Engvall M; Wredenberg A; Hedestam GBK; Dopico XC; Rorbach J
Article: LANCET REGIONAL HEALTH-EUROPE. 2023;30:100646
Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study.
Vikström L; Fjällström P; Gwon Y-D; Sheward DJ; Wigren-Byström J; Evander M; Bladh O; Widerström M; Molnar C; Rasmussen G; Bennet L; Åberg M; Björk J; Tevell S; Thålin C; Blom K; Klingström J; Murrell B; Ahlm C; Normark J; Johansson AF; Forsell MNE
Article: NATURE COMMUNICATIONS. 2023;14(1):2249
Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
Chernyshev M; Sakharkar M; Connor RI; Dugan HL; Sheward DJ; Rappazzo CG; Stalmarck A; Forsell MNE; Wright PF; Corcoran M; Murrell B; Walker LM; Hedestam GKB
Article: FRONTIERS IN VIROLOGY. 2023;3:1128253
Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses
Pushparaj P; Nicoletto A; Castro Dopico X; Sheward DJ; Kim S; Ekstrom S; Murrell B; Corcoran M; Karlsson Hedestam GB
Article: JCI INSIGHT. 2023;8(1):e165299
Longitudinal single-cell analysis of SARS-CoV-2-reactive B cells uncovers persistence of early-formed, antigen-specific clones
Scharf L; Axelsson H; Emmanouilidi A; Mathew NR; Sheward DJ; Leach S; Isakson P; Smirnov IV; Marklund E; Miron N; Andersson L-M; Gisslen M; Murrell B; Lundgren A; Bemark M; Angeletti D
Article: IMMUNITY. 2023;56(1):193-206.e7
Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies
Pushparaj P; Nicoletto A; Sheward DJ; Das H; Dopico XC; Vidakovics LP; Hanke L; Chernyshev M; Narang S; Kim S; Fischbach J; Ekstrom S; McInerney G; Hallberg BM; Murrell B; Corcoran M; Hedestam GBK
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:941281
SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses
Christensen D; Polacek C; Sheward DJ; Hanke L; McInerney G; Murrell B; Hartmann KT; Jensen HE; Zimmermann J; Jungersen G; Illigen KE; Isling LK; Fernandez-Antunez C; Ramirez S; Bukh J; Pedersen GK
Article: EBIOMEDICINE. 2022;84:104248
Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy
Christensen D; Polacek C; Sheward DJ; Hanke L; Moliner-Morro A; McInerney G; Murrell B; Hartmann KT; Jensen HE; Jungersen G; Illigen K; Isling LK; Jensen RF; Hansen JS; Rosenkrands I; Fernandez-Antunez C; Ramirez S; Follmann F; Bukh J; Pedersen GK
Article: SCIENCE ADVANCES. 2022;8(12):eabm0220
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies
Hanke L; Sheward DJ; Pankow A; Vidakovics LP; Karl V; Kim C; Urgard E; Smith NL; Astorga-Wells J; Ekstrom S; Coquet JM; McInerney GM; Murrell B
Article: CELL REPORTS. 2022;38(3):110242
SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display
Ehling RA; Weber CR; Mason DM; Friedensohn S; Wagner B; Bieberich F; Kapetanovic E; Vazquez-Lombardi R; Di Roberto RB; Hong K-L; Wagner C; Pataia M; Overath MD; Sheward DJ; Murrell B; Yermanos A; Cuny AP; Savic M; Rudolf F; Reddy ST
Article: NATURE COMMUNICATIONS. 2022;13(1):155
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
Hanke L; Das H; Sheward DJ; Vidakovics LP; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hallberg BM; Murrell B; McInerney GM
Article: FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY. 2022;10:1083232
Silver nanoparticles with excellent biocompatibility block pseudotyped SARS-CoV-2 in the presence of lung surfactant
Gupta G; Hamawandi B; Sheward DJ; Murrell B; Hanke L; McInerney G; Blosi M; Costa AL; Toprak MS; Fadeel B
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2022;11(3):e1379
Probabilistic classification of anti-SARS-CoV-2 antibody responses improves seroprevalence estimates
Dopico XC; Muschiol S; Grinberg NF; Aleman S; Sheward DJ; Hanke L; Ahl M; Vikstrom L; Forsell M; Coquet JM; McInerney G; Dillner J; Bogdanovic G; Murrell B; Albert J; Wallace C; Hedestam GBK
Article: JOURNAL OF INTERNAL MEDICINE. 2021;290(3):666-676
Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden
Castro Dopico X; Muschiol S; Christian M; Hanke L; Sheward DJ; Grinberg NF; Rorbach J; Bogdanovic G; Mcinerney GM; Allander T; Wallace C; Murrell B; Albert J; Karlsson Hedestam GB
Article: CELL REPORTS MEDICINE. 2021;2(4):100252
SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses
Mandolesi M; Sheward DJ; Hanke L; Ma J; Pushparaj P; Vidakovics LP; Kim C; Adori M; Lenart K; Lore K; Dopico XC; Coquet JM; McInerney GM; Hedestam GBK; Murrell B
Article: SCIENTIFIC REPORTS. 2021;11(1):3125
DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
Szurgot I; Hanke L; Sheward DJ; Vidakovics LP; Murrell B; McInerney GM; Liljestrom P
Article: EBIOMEDICINE. 2021;63:103197
Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice
Worzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Hedestam GBK; Murrell B; Christensen D; Pedersen GK
Article: BIOMOLECULES. 2020;10(12):E1661-1661
Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs
Moliner-Morro A; J. Sheward D; Karl V; Perez Vidakovics L; Murrell B; McInerney GM; Hanke L
Article: NATURE COMMUNICATIONS. 2020;11(1):5588
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Custodio TF; Das H; Sheward DJ; Hanke L; Pazicky S; Pieprzyk J; Sorgenfrei M; Schroer MA; Gruzinov AY; Jeffries CM; Graewert MA; Svergun DI; Dobrev N; Remans K; Seeger MA; McInerney GM; Murrell B; Haellberg BM; Loew C
Article: NATURE COMMUNICATIONS. 2020;11(1):4420
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
Hanke L; Perez LV; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Hedestam GBK; Haellberg BM; Murrell B; McInerney GM
Article: SCIENCE TRANSLATIONAL MEDICINE. 2018;10(425):eaam6354
Integrin α₄β₇ expression on peripheral blood CD4⁺ T cells predicts HIV acquisition and disease progression outcomes
Sivro A; Schuetz A; Sheward D; Joag V; Yegorov S; Liebenberg LJ; Yende-Zuma N; Stalker A; Mwatelah RS; Selhorst P; Garrett N; Samsunder N; Balgobin A; Nawaz F; Cicala C; Arthos J; Fauci AS; Anzala AO; Kimani J; Bagaya BS; Kiwanuka N; Williamson C; Kaul R; Passmore J-AS; Phanuphak N; Ananworanich J; Ansari A; Karim QA; Karim SSA; McKinnon LR
Journal article: PLOS PATHOGENS. 2017;13(9):e1006641
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker L-G; Hoelscher M; Maboko L; Makhema J; Robb ML; Karim SA; Karim QA; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
Journal article: PLOS PATHOGENS. 2017;13(1):e1006074
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape
Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Karim SSA; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
Article: PLOS PATHOGENS. 2016;12(7):e1005742
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker L-G; Hoelscher M; Maboko L; Makhema J; Robb ML; Karim SA; Karim QA; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
Article: JOURNAL OF INFECTIOUS DISEASES. 2015;212(6):904-908
HIV-1 Superinfection Resembles Primary Infection
Sheward DJ; Ntale R; Garrett NJ; Woodman ZL; Karim SSA; Williamson C
Journal article: RETROVIROLOGY. 2015;12:54
South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication
Richardson SI; Gray ES; Mkhize NN; Sheward DJ; Lambson BE; Wibmer CK; Masson L; Werner L; Garrett N; Passmore J-AS; Karim QA; Karim SSA; Williamson C; Moore PL; Morris L
Journal article: JOURNAL OF INFECTIOUS DISEASES. 2015;211(9):1461-1466
Differences in HIV Type 1 Neutralization Breadth in 2 Geographically Distinct Cohorts in Africa
Bandawe GP; Moore PL; Werner L; Gray ES; Sheward DJ; Madiga M; Nofemela A; Thebus R; Marais JC; Maboko L; Karim SSA; Hoelscher M; Morris L; Williamson C
Article: NATURE. 2014;509(7498):55-62
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose NA; Schramm CA; Gorman J; Moore PL; Bhiman JN; DeKosky BJ; Ernandes MJ; Georgiev IS; Kim HJ; Pancera M; Staupe RP; Altae-Tran HR; Bailer RT; Crooks ET; Cupo A; Druz A; Garrett NJ; Hoi KH; Kong R; Louder MK; Longo NS; McKee K; Nonyane M; O'Dell S; Roark RS; Rudicell RS; Schmidt SD; Sheward DJ; Soto C; Wibmer CK; Yang Y; Zhang Z; Mullikin JC; Binley JM; Sanders RW; Wilson IA; Moore JP; Ward AB; Georgiou G; Williamson C; Karim SSA; Morris L; Kwong PD; Shapiro L; Mascola JR
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 2014;52(3):844-848
Limited HIV-1 Superinfection in Seroconverters from the CAPRISA 004 Microbicide Trial
Redd AD; Mullis CE; Wendel SK; Sheward D; Martens C; Bruno D; Werner L; Garrett NJ; Karim QA; Williamson C; Porcella SF; Quinn TC; Karim SSA
Article: VIROLOGY JOURNAL. 2013;10:347
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models
Lacerda M; Moore PL; Ngandu NK; Seaman M; Gray ES; Murrell B; Krishnamoorthy M; Nonyane M; Madiga M; Wibmer CK; Sheward D; Bailer RT; Gao H; Greene KM; Karim SSA; Mascola JR; Korber BTM; Montefiori DC; Morris L; Williamson C; Seoighe C
Article: MOLECULAR BIOLOGY AND EVOLUTION. 2013;30(5):1196-1205
FUBAR: A Fast, Unconstrained Bayesian AppRoximation for Inferring Selection
Murrell B; Moola S; Mabona A; Weighill T; Sheward D; Pond SLK; Scheffler K
Article: JOURNAL OF VIROLOGY. 2013;87(9):4882-4894
Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies
Moore PL; Sheward D; Nonyane M; Ranchobe N; Hermanus T; Gray ES; Karim SSA; Williamson C; Morris L
Article: NATURE MEDICINE. 2012;18(11):1688-1692
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
Moore PL; Gray ES; Wibmer CK; Bhiman JN; Nonyane M; Sheward DJ; Hermanus T; Bajimaya S; Tumba NL; Abrahams M-R; Lambson BE; Ranchobe N; Ping L; Ngandu N; Karim QA; Karim SSA; Swanstrom RI; Seaman MS; Williamson C; Morris L
Article: JOURNAL OF VIROLOGY. 2011;85(7):3128-3141
Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop
Moore PL; Gray ES; Sheward D; Madiga M; Ranchobe N; Lai Z; Honnen WJ; Nonyane M; Tumba N; Hermanus T; Sibeko S; Mlisana K; Karim SSA; Williamson C; Pinter A; Morris L
Journal article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2010;14:e20
Understanding Anti-HIV Antibody Targets
Moore P; Gray E; Madiga M; Ranchobe N; Lambson B; Abrahams M-R; Bandawe G; Sheward D; Thebus R; Mlisana K; Karim SA; Williamson C; Morris L
Show more

All other publications

Preprint: BIORXIV. 2023
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster
Marking U; Bladh O; Aguilera K; Yang Y; Norin NG; Blom K; Hober S; Klingström J; Havervall S; Åberg M; Sheward D; Thålin C
Preprint: BIORXIV. 2023
Sensitivity of BA.2.86 to prevailing neutralising antibody responses
Sheward DJ; Yang Y; Westerberg M; Öling S; Muschiol S; Sato K; Peacock TP; Hedestam GBK; Albert J; Murrell B
Preprint: RESEARCH SQUARE. 2022
Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
Chernyshev M; Sakharkar M; Connor R; Dugan H; Sheward D; Rappazzo G; Stålmarck A; Forsell M; Wright P; Corcoran M; Murrell B; Walker L; Hedestam GK
Preprint: BIORXIV. 2022
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
Sheward D; Kim C; Fischbach J; Muschiol S; Ehling R; Björkström N; Karlsson Hedestam G; Reddy S; Albert J; Peacock T; Murrell B
Preprint: BIORXIV. 2022
Evasion of neutralizing antibodies by Omicron sublineage BA.2.75
Sheward D; Kim C; Fischbach J; Muschiol S; Ehling R; Björkström N; Karlsson Hedestam G; Reddy S; Albert J; Peacock T; Murrell B
Preprint: BIORXIV. 2022
Structural basis of Omicron neutralization by affinity-matured public antibodies
Sheward D; Pushparaj P; Das H; Kim C; Kim S; Hanke L; Dyrdak R; McInerney G; Albert J; Murrell B; Karlsson Hedestam G; Hällberg M
Preprint: BIORXIV. 2021
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
Sheward D; Kim C; Ehling R; Pankow A; Dopico XC; Martin D; Reddy S; Dillner J; Karlsson Hedestam G; Albert J; Murrell B
Preprint: BIORXIV. 2021
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies
Hanke L; Sheward D; Pankow A; Vidakovics LP; Karl V; Kim C; Urgard E; Smith N; Astorga-Wells J; Ekström S; Coquet J; McInerney G; Murrell B
Preprint: BIORXIV. 2021
Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a heterotypic boost
Sheward D; Mandolesi M; Urgard E; Kim C; Hanke L; Vidakovics LP; Pankow A; Smith N; Dopico XC; McInerney G; Coquet J; Hedestam GK; Murrell B
Preprint: BIORXIV. 2021
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
Hanke L; Das H; Sheward D; Vidakovics LP; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith N; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen G; Coquet J; Hällberg M; Murrell B; McInerney G
Preprint: BIORXIV. 2021
Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2
Ehling R; Weber C; Mason D; Friedensohn S; Wagner B; Bieberich F; Kapetanovic E; Vazquez-Lombardi R; Di Roberto R; Hong K-L; Wagner C; Sheward D; Murrell B; Yermanos A; Cuny A; Savic M; Rudolf F; Reddy S
Preprint: SSRN. 2021
Single-Cell Sequencing of Plasma Cells from COVID-19 Patients Reveals Highly Expanded Clonal Lineages Produce Specific and Neutralizing Antibodies to SARS-CoV-2
Ehling R; Weber C; Mason D; Friedensohn S; Wagner B; Bieberich F; Kapetanovic E; Vazquez-Lombardi R; Roberto RBD; Hong K-L; Wagner C; Sheward D; Murrel B; Yermanos A; Cuny A; Savic M; Rudolf F; Reddy S
Preprint: MEDRXIV. 2020
Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden
Dopico XC; Muschiol S; Christian M; Hanke L; Sheward D; Grinberg N; Rorbach J; Bogdanovic G; Mcinerney G; Allander T; Wallace C; Murrell B; Albert J; Hedestam GK
Preprint: BIORXIV. 2020
Estimating the timing of HIV infection from unmutated sequences
Pankow A; Christian M; Smith N; Sheward D; Murrell B
Preprint: BIORXIV. 2020
SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses
Mandolesi M; Sheward D; Hanke L; Ma J; Pushparaj P; Perez Vidakovics L; Kim C; Loré K; Castro Dopico X; Coquet J; McInerney G; Karlsson Hedestam G; Murrell B
Preprint: MEDRXIV. 2020
Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses
Dopico X; Hanke L; Sheward D; Muschiol S; Aleman S; Grinberg N; Adori M; Christian M; Vidakovics LP; Kim C; Khoenkhoen S; Pushparaj P; Morro AM; Mandolesi M; Ahl M; Forsell M; Coquet J; Corcoran M; Rorbach J; Dillner J; Bogdanovic G; McInerney G; Allander T; Murrell B; Wallace C; Albert J; Karlsson Hedestam G
Preprint: BIORXIV. 2020
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Custódio T; Das H; Sheward D; Hanke L; Pazicky S; Pieprzyk J; Sorgenfrei M; Schroer M; Gruzinov A; Jeffries C; Graewert M; Svergun D; Dobrev N; Remans K; Seeger M; McInerney G; Murrell B; Hällberg M; Löw C
Preprint: BIORXIV. 2020
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
Hanke L; Perez LV; Sheward D; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Hedestam GK; Hällberg M; Murrell B; McInerney G
Preprint: SSRN. 2020
Adjuvanted SARS-CoV-2 Spike Protein Elicits Neutralizing Antibodies and CD4 T Cell Responses after a Single Immunization in Mice
Wørzner K; Sheward D; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Hedestam GK; Murrel B; Christensen D; Pedersen G
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2016;32:261
Features of Recently Transmitted HIV-1 Clade C Viruses That Impact Antibody Recognition: Implications for Active and Passive Immunization
Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Tang H; Bandawe GP; Hraber P; Tumba N; Moore PL; Morris L; Montefiori DC; Williamson C
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2016;32:46
Hypo-osmolar Formulation of TFV Enemas Promotes Uptake and Transformation of TFV to TFV-DP in Tissues and Prevents SHIV/SIV Infection
Xiao P; Gumber S; Marzinke M; Ensign L; Fuchs E; Hendrix C; Villinger F
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2016;32:60
HIV-1 Superinfection Can Lead to Potent Neutralization of the Superinfecting Virus but Is Not Sufficient to Elicit Broadly Neutralizing Antibodies
Sheward DJ; Nonyane M; Marais J; Bhiman JN; Garrett N; Karim SA; Woodman ZL; Morris L; Moore PL; Williamson C
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2014;30:A34
Maturation of Broadly Neutralizing V1V2-directed Antibodies in the Context of Autologous Viral Escape
Bhiman JN; Doria-Rose NA; Wibmer CK; Sheward DJ; Williamson C; Karim SSA; Kwong PD; Mascola JR; Morris L; Moore PL
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2014;30:A225
Changes in Viral Population Kinetics Following HIV-1 Superinfection
Logan MG; Sheward DJ; Anthony C; Garret N; Williamson C
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2014;30:A20-A21
Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation
Wibmer CK; Sheward DJ; Bhiman JN; Ndabambi N; Elliot DH; Rouelle J; Smira A; Karim SSA; Robinson JE; Morris L; Williamson C; Moore PL
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2014;30:A56
The Sequence of the α4β7-binding Motif on Gp120 of Transmitted/Founder Viruses Contributes to the Dependence on the Integrin for HIV Infection
Richardson SI; Gray E; Mkhize N; Sheward D; Lambson B; Wibmer K; Masson L; Werner L; Garett N; Passmore J-A; Abdool-Karim S; Williamson C; Moore P; Morris L
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2014;30:A226
Outgrowth of Subtype C Envelope Viral Populations in Dual-infected Individuals Is Not Always Associated with Entry Efficiency
Omar SSA; Sheward D; Williamson C; Woodman Z
Letter: AIDS. 2014;28(1):142-144
Response to 'single genome amplification and sequencing methods require appropriate thresholds for viral transmission and evolution studies'
Abrahams M-R; Sheward D; Williamson C
Letter: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012;109(21):E1330
Degenerate Primer IDs and the Birthday Problem
Sheward DJ; Murrell B; Williamson C
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2011;27(10):A40
Superinfection Results in Potent Neutralizing Antibody Responses to the Superinfecting Virus, but Does Not Necessarily Enhance Neutralization Breadth
Sheward DJ; Moore PL; Madiga MC; Gray ES; Ntale R; Woodman ZL; Bhiman J; Harvey H; Sibeko S; Mlisana K; Karim SSA; Morris L; Williamson C
Conference publication: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2010;26(10):A24-A25
Mapping of residues critical for neutralisation by a broadly cross-neutralising antibody targeting a quaternary epitope on the HIV-1 Envelope
Sheward DJ; Moore PL; Thebus R; Gray ES; Madiga M; Ranchobe N; Mlisana K; Karim SSA; Morris L; Williamson C
Show more

Employments

Assistant Professor, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2024-2030
Research Specialist, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2024-2024
Postdoctoral Researcher, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2022-2024

Selected publications

Articles

All other publications

Employments

News from KI

Events from KI